{
"main_header": {
"sid": 793005,
"name": "Glaxosmi. Pharma",
"stock_name": "Glaxosmi. Pharma",
"full_name": "Glaxosmithkline Pharmaceuticals Ltd",
"name_url": "stocks-analysis/glaxosmi-pharma",
"exchange": 0,
"exchangecode": "",
"country_id": 34,
"currency": "INR",
"cmp": "2,315.00",
"chg": -9.3,
"chgp": "-0.4%",
"dir": -1,
"prev_price": "2,324.30",
"mcapval": "38,982.00 Cr",
"mcap": "Mid Cap",
"scripcode": 500660,
"symbol": "GLAXO",
"ind_name": "Pharmaceuticals & Biotechnology",
"ind_code": 4,
"indexname": "",
"isin": "INE159A01016",
"curr_date": "Apr 02",
"curr_time": "",
"bse_nse_vol": "1.12 lacs",
"exc_status": "Active",
"traded_date": "Apr 02, 2026",
"traded_date_str": "2026 04 02",
"score": "",
"scoreText": "",
"Live": 0,
"market_time": 0,
"is_blur": 1,
"is_blur_class": "blur-register-score-header",
"is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/glaxosmi-pharma-793005-0&utm_source=Spage_Header_Score",
"mojoone": {
"ismore": 0,
"all_data": []
}
},
"news": {
"results": [],
"total": 0,
"sid": "793005",
"stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/glaxosmithkline-pharmaceuticals-793005"
},
"announcements": [
{
"caption": "Disclosure Under Regulation 30",
"datetime": "31-Mar-2026",
"details": "As per attachment",
"source": "BSE"
},
{
"caption": "Closure of Trading Window",
"datetime": "25-Mar-2026",
"details": "As per attachment",
"source": "BSE"
},
{
"caption": "Disclosure Under Regulation 30",
"datetime": "24-Mar-2026",
"details": "As per attachment",
"source": "BSE"
}
],
"corporate_actions": [
{
"img": "board-meeting.svg",
"title": "BOARD MEETING",
"msg": "<span>No</span> Upcoming Board Meetings",
"data": []
},
{
"img": "dividend.svg",
"title": "DIVIDEND",
"msg": "",
"data": [
{
"txt": "Glaxosmithkline Pharmaceuticals Ltd has declared <strong>420%</strong> dividend, ex-date: 30 May 25",
"dt": "2025-05-30",
"middle_text": "Dividend Alert"
}
]
},
{
"img": "splits.svg",
"title": "SPLITS",
"msg": "No <strong>Splits</strong> history available",
"data": []
},
{
"img": "bonus.svg",
"title": "BONUS",
"msg": "",
"data": [
{
"txt": "Glaxosmithkline Pharmaceuticals Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 11 Sep 18",
"dt": "2018-09-11",
"middle_text": "Bonus Alert"
}
]
},
{
"img": "rights-issues.svg",
"title": "RIGHTS",
"msg": "No <strong>Rights</strong> history available",
"data": []
}
]
}Disclosure Under Regulation 30
31-Mar-2026 | Source : BSEAs per attachment
Closure of Trading Window
25-Mar-2026 | Source : BSEAs per attachment
Disclosure Under Regulation 30
24-Mar-2026 | Source : BSEAs per attachment
Corporate Actions
No Upcoming Board Meetings
Glaxosmithkline Pharmaceuticals Ltd has declared 420% dividend, ex-date: 30 May 25
No Splits history available
Glaxosmithkline Pharmaceuticals Ltd has announced 1:1 bonus issue, ex-date: 11 Sep 18
No Rights history available
Name: MOJO Markets Private Limited (Research Entity) (SEBI Registration No. INH000021942) (CIN:U74900MH2015PTC264951)
Registered & Correspondence Address: Benefice Business House, Office No. 3B, 3rd Floor, C.S. 242, Mathuradas Mills Estate, N.M. Joshi Marg, Tulsi Pipe Road, Lower Parel West, Mumbai- 400013
For queries or grievances, please contact us on support@mojoinfinity.com, Phone : 022-35121239
"Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors."